Answers are grounded in this paper and cite their sources.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is curative for pediatric hematological disorders, yet acute graft-versus-host disease (aGVHD) remains a major complication. Emerging evidence links gut microbiota dysbiosis to aGVHD pathogenesis, but pediatric-specific microbiome signatures and their predictive value are incompletely understood. We prospectively collected 537 fecal samples from 118 pediatric allo-HSCT recipients at five timepoints (pre-transplant, day 0, day 14, day 30, and day 90 post-transplant). 16S rRNA gene sequencing was performed to assess microbial diversity, composition, and predicted functional pathways. Machine learning approaches were applied to identify microbial signatures associated with aGVHD development and treatment response. At baseline, GVHD + patients had lower Shannon diversity than GVHD − patients ( P = 0.041), with a further within-group decline to a day-14 nadir ( P = 0.008); no significant difference in beta-diversity was observed between groups at any time point. In internally validated (cross-validated) models, pre-transplant and day 0 microbiota composition was associated with subsequent aGVHD development (AUC 0.903–0.954); these estimates are likely optimistic and require external validation. Feature selection identified pre-transplant ASVs enriched in GVHD + patients (predominantly Proteobacteria and Actinobacteriota) and in GVHD − patients (including Stenotrophomonas, whose interpretation is uncertain given its recognition as a common sequencing contaminant). In exploratory analyses, responders to first-line aGVHD therapy showed more stable diversity trajectories than non-responders, although recovery of SCFA-producing taxa was not uniform between groups. Predicted (PICRUSt2) functional analysis suggested lower abundance of short-chain fatty acid and carbohydrate metabolic pathways in GVHD + patients. These findings identify a pediatric aGVHD-associated microbiome signature that, pending confirmation in larger multicentre cohorts and external validation, may contribute to risk stratification; modulation of the gut microbiota remains a candidate supportive strategy in pediatric allo-HSCT.
No takes yet. Share an insight, caveat, or question.
Qu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: